ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Drug Manufacturers - Specialty & Generic

Healthcare
$71.47 -1.76%

-$1.42 today

Market cap
$1.62B
Beta
0.44
P/E (TTM)
18.5
EPS (TTM)
$4.29
52W Low $62.61High $99.50

Volume 0.29M

Average 0.35M

ANIP Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

ANI Pharmaceuticals, Inc.NASDAQ: ANIP

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 51.8%

Gross margin was 51.8% in Q1 FY2026, down 11.2 pp from a year earlier. On a trailing-twelve-month basis it was 65.9%, up 6.6 pp year over year. Over 3 fiscal years it narrowed by 5.1 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
51.8%-44.4 pp QoQ
Last fiscal yearDec 2025
51.0%-8.3 pp YoY
LTMMar 2026
65.9%+6.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-11.2 pp——
1 year-8.3 pp——
3 years-5.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
51.0%
Year-over-year change
-8.3pp

Gross Margin vs competitors

How ANIP compares with its peers on the latest reported figures

  • ANIP's LTM Mar 2026 gross margin of 65.9% is the 3rd highest of the 11 companies compared; the peer median is 51.0%.
  • Its year-over-year change of +6.6 pp is the highest of 10, against a peer median of -0.4 pp.
  • Over three fiscal years its change of -5.1 pp compares with a peer median of +0.8 pp.
ANIP Competitors Peer median
Gross Margin for ANIP and competitors
Company Period LTM level YoY 3-year change
HROWHarrow Health, Inc.LTM Mar 202674.1% -0.4 pp+3.7 pp
BHCBausch Health Companies Inc.LTM Jun 202671.8% +1.1 pp-0.3 pp
ANIPANI Pharmaceuticals, Inc.LTM Mar 202665.9% +6.6 pp-5.1 pp
EOLSEvolus, Inc.LTM Mar 202665.5% -2.3 pp+4.5 pp
COLLCollegium Pharmaceutical, Inc.LTM Mar 202660.7% +3.0 pp+14.2 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 202652.5% +2.9 pp+5.1 pp
RDYDr. Reddy's Laboratories LimitedLTM Sep 202649.5% -7.0 pp-3.9 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202647.3% -3.3 pp-0.4 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 202639.3% +1.7 pp+1.9 pp
VTRSViatris Inc.LTM Jun 202634.8% -1.8 pp-4.9 pp
LFCRLifecore Biomedical, Inc.LTM Mar 202631.2% —-3.8 pp
Peer median (excluding ANIP) 51.0%-0.4 pp+0.8 pp

Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue216.14M316.39M486.82M614.38M883.37M
Cost of Revenue100.61M138.79M181.51M250.21M432.73M
Gross Profit115.53M177.6M305.3M364.17M450.64M
Gross Margin53.5%56.1%62.7%59.3%51.0%
Research & Development11.37M22.32M34.29M44.58M51.66M
Selling, General & Admin84.29M124.04M161.7M249.64M317.75M
Operating Expenses155.32M212.88M258.33M363.58M369.41M
Depreciation & Amortization47.25M59.65M59.79M67.73M91.42M
EBITDA3.12M25.04M106.6M63.12M207.27M
EBITDA Margin1.4%7.9%21.9%10.3%23.5%
Operating Income(39.79M)(35.28M)46.97M584K81.23M
Operating Margin-18.4%-11.2%9.6%0.1%9.2%
Interest Income00000
Interest Expense11.92M28.05M26.94M17.6M20.06M
Other Income / Expenses(16.27M)(27.38M)(27.1M)(22.8M)14.56M
Income Before Tax(56.06M)(62.67M)19.87M(22.21M)95.79M
Pre-Tax Margin-25.9%-19.8%4.1%-3.6%10.8%
Income Tax Expense(13.46M)(14.77M)1.09M(3.69M)17.45M
Net Income(42.6M)(47.9M)18.78M(18.52M)78.34M
Net Margin-19.7%-15.1%3.9%-3.0%8.9%
EPS (Basic)(3.40)(3.05)0.95(1.04)3.50
EPS (Diluted)(3.40)(3.05)0.94(1.04)3.32
Weighted Avg Shares12.6M16.26M18M19.32M20.05M
Weighted Avg Shares (Diluted)12.6M16.26M18.19M19.32M21.23M

ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Intrinsic Alpha fair value

Locked

Current Price

$71.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.